company background image
NEXI

NexImmune NasdaqGM:NEXI Stock Report

Last Price

US$0.39

Market Cap

US$10.1m

7D

7.5%

1Y

-86.9%

Updated

26 Jan, 2023

Data

Company Financials +

NEXI Stock Overview

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.

NEXI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

NexImmune, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NexImmune
Historical stock prices
Current Share PriceUS$0.39
52 Week HighUS$4.91
52 Week LowUS$0.19
Beta0
1 Month Change75.79%
3 Month Change-46.24%
1 Year Change-86.92%
3 Year Changen/a
5 Year Changen/a
Change since IPO-98.47%

Recent News & Updates

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Sep 07
NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Neximmune GAAP EPS of -$0.69 misses by $0.01

Aug 15

Recent updates

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Sep 07
NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

May 26
Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Dec 19
We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Shareholder Returns

NEXIUS BiotechsUS Market
7D7.5%1.6%3.1%
1Y-86.9%10.5%-8.5%

Return vs Industry: NEXI underperformed the US Biotechs industry which returned 8.3% over the past year.

Return vs Market: NEXI underperformed the US Market which returned -9.4% over the past year.

Price Volatility

Is NEXI's price volatile compared to industry and market?
NEXI volatility
NEXI Average Weekly Movement16.2%
Biotechs Industry Average Movement12.2%
Market Average Movement7.0%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: NEXI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: NEXI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201174Kristi Joneshttps://www.neximmune.com

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage.

NexImmune, Inc. Fundamentals Summary

How do NexImmune's earnings and revenue compare to its market cap?
NEXI fundamental statistics
Market CapUS$10.09m
Earnings (TTM)-US$61.14m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NEXI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$61.14m
Earnings-US$61.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.34
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NEXI perform over the long term?

See historical performance and comparison